GLP1R and Hypoglycemia: Glucagon like peptide-1 receptor agonists (GLP-1 RAs) are a relatively new class of injectable drugs that have emerged as an attractive second- or third-line therapeutic option because of their association with improved glycemic control, lower hypoglycemia rate and weight loss, although gastrointestinal GLP-1 RAs side effects have also been reported [6, 7].